Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab Auto-Injector Usability Study
NCT03491904Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fasinumab in knee osteoarthritis (OA) and osteoarthritis of the hip (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percentage of device-associated product technical failure (PTF) at 16 weeks. Started Jan 2019; status: completed.
02
Drugs
fasinumab
03
Conditions
knee osteoarthritis (OA)osteoarthritis of the hip
Beyond the preview
Go deeper on NCT03491904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491904.